Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmon, Matthew, White, Helen E., Zizkova, Hana, Gottschalk, Andrea, Motlova, Eliska, Cerveira, Nuno, Colomer, Dolors, Coriu, Daniel, Franke, Georg N., Gottardi, Enrico, Izzo, Barbara, Jurcek, Tomas, Lion, Thomas, Schäfer, Vivien, Venturi, Claudia, Vigneri, Paolo, Zawada, Magdalena, Zuna, Jan, Hovorkova, Lenka, Koblihova, Jitka, Klamova, Hana, Markova, Marketa Stastna, Srbova, Dana, Benesova, Adela, Polivkova, Vaclava, Zackova, Daniela, Mayer, Jiri, Roeder, Ingo, Glauche, Ingmar, Ernst, Thomas, Hochhaus, Andreas, Polakova, Katerina Machova, Cross, Nicholas C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252903/
https://www.ncbi.nlm.nih.gov/pubmed/35676453
http://dx.doi.org/10.1038/s41375-022-01612-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252903/
https://www.ncbi.nlm.nih.gov/pubmed/35676453
http://dx.doi.org/10.1038/s41375-022-01612-2

Ejemplares similares